The global tumor ablation market was valued at USD 1,703.26 million in 2024 and is projected to expand at a CAGR of 13.30% from 2025 to 2032, reaching USD 4,595.68 million by 2032. This growth is primarily fueled by the rising global cancer burden, which is increasing the demand for effective, minimally invasive treatment options such as tumor ablation. The preference for less invasive procedures continues to grow due to benefits like quicker recovery, fewer complications, and lower costs compared with traditional surgical approaches.
Moreover, advancements in ablation technologies—including radiofrequency, microwave, and cryoablation—are improving procedural precision, safety, and efficacy, making these treatments more appealing to clinicians and patients alike. Strategic initiatives, such as mergers, acquisitions, and partnerships among leading companies, are further enhancing product availability and fostering innovation. Collectively, these factors are expected to drive the adoption and growth of tumor ablation therapies worldwide over the forecast period.
DelveInsight’s Tumor Ablation Market Insights report provides a comprehensive analysis of the current and forecast market landscape, including market drivers, challenges, trends, key players, and individual company market shares shaping the global tumor ablation market.
Request for sample pages @ https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Tumor Ablation Market Report
-
The Tumor Ablation market is expected to experience moderate growth between 2025 and 2032. According to DelveInsight estimates, North America is likely to maintain its position as the largest regional market during the forecast period.
-
Key players operating in the Tumor Ablation market include Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott, Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew, among others.
-
Notable recent developments include Medtronic obtaining FDA clearance for its OsteoCool™ 2.0 bone tumor ablation system in March 2024, and Stryker receiving FDA approval for its OptaBlate™ bone tumor ablation system in September 2022, reflecting ongoing innovation in the sector.
To read more about the latest highlights related to the Tumor Ablation market, get a snapshot of the key highlights entailed in the Global Tumor Ablation Market Report
Tumor Ablation Overview
Tumor ablation is a minimally invasive treatment that eliminates cancerous or abnormal tissue by applying extreme heat or cold, avoiding the need for conventional open surgery. This technique is frequently used for tumors in the liver, lungs, kidneys, and bones, especially in cases where surgery is not feasible due to patient health or the tumor’s location.
Tumor Ablation Market Insights
North America is expected to dominate the global tumor ablation market in 2024, holding the largest regional share. This leadership is primarily driven by the region’s high incidence of cancers, particularly liver, kidney, and lung cancers, which increases the demand for advanced, effective treatment options like tumor ablation. The region’s well-established healthcare infrastructure, broad adoption of minimally invasive procedures, and ongoing technological advancements in ablation devices—including microwave and radiofrequency systems—further support market growth. Additionally, favorable reimbursement policies, strong R&D investment, and strategic collaborations among key industry players enhance innovation, product accessibility, and reinforce North America’s market dominance.
According to GLOBOCAN (2024), North America recorded approximately 79,800 new kidney cancer cases in 2022, projected to increase to 103,000 by 2045. In total, the region reported 2.67 million new cancer cases in 2022, expected to rise to 3.83 million by 2045. The growing cancer burden, particularly in organs such as the liver, kidney, and lungs, is driving demand for minimally invasive therapies. Tumor ablation techniques, including radiofrequency and microwave ablation, allow for precise tumor targeting with shorter recovery times, making them a preferred alternative to traditional surgery and significantly contributing to market growth in North America.
To know more about why North America is leading the market growth in the Tumor Ablation market, get a snapshot of the Tumor Ablation Market Outlook
Tumor Ablation Market Dynamics
According to the World Cancer Research Fund (2024), more than 866,136 new liver cancer cases were reported worldwide in 2022. Similarly, GLOBOCAN (2024) data shows that kidney cancer accounted for around 435,000 new cases globally in 2022, with projections estimating an increase to 693,000 cases by 2045.
Tumor ablation techniques—including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation—have proven highly effective for treating localized tumors in organs such as the liver and kidneys. These minimally invasive methods are particularly valuable when conventional surgery is too risky or unfeasible due to patient health conditions. Given that hepatocellular carcinoma (HCC) is one of the most common liver cancers globally, ablation therapies are increasingly relied upon for early-stage patients or those ineligible for surgical resection. Similarly, the rising incidence of renal cell carcinoma has fueled demand for ablation procedures that effectively target cancer while preserving kidney function.
The tumor ablation market is also gaining momentum from strategic initiatives by leading companies, including new product launches and clinical innovations aimed at expanding treatment options. For instance, in April 2023, Compal Electronics, a Taiwan-based firm, launched a radiofrequency ablation system for percutaneous and intraoperative soft tissue ablation, including treatment for unresectable liver tumors. Developments like these are significantly contributing to global market growth.
Tumor Ablation Market Drivers:
-
Rising number of endovascular and interventional procedures.
-
Growing demand for minimally invasive vascular closure solutions.
-
Tumor Ablation Market Barriers:
-
Risk of device-related complications and failures.
-
High cost of advanced closure systems limiting widespread adoption.
Get a sneak peek at the Tumor Ablation market dynamics @ https://www.delveinsight.com/sample-request/tumor-ablation-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Scope of the Tumor Ablation Market Report:
-
Coverage: Global
-
Study Period: 2022 to 2032
-
Key Tumor Ablation Companies: Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott., Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew, Hologic, Inc.,, and others.
Which MedTech key players in the Tumor Ablation market are set to emerge as the trendsetter, explore @ Tumor Ablation Companies
Table of Contents
1. Tumor Ablation Market Report Introduction
2. Tumor Ablation Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Tumor Ablation Market Key Factors Analysis
6. Tumor Ablation Market Porter’s Five Forces Analysis
7. Tumor Ablation Market Layout
8. Tumor Ablation Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/